Medtech
The I-Hart study, which enrolled 40 people with Type I diabetes, found that Dexcom’s device reduced patients’ time spent in hypoglycemia by 43 minutes.
With a trial on hold for more than six months, InVivo has been burning through cash and may not have enough financing to continue operations for much longer.
The $15 million offering will be open not only to individual accredited investors, but also to qualified institutional buyers.
The company will open a new $11.6 million plant in Green County.
The medical device manufacturer will soon call Berkeley County home.
The 55-to-43 vote for Azar ushers in his return to the government’s largest domestic agency, where he held senior roles previously.
But for now, the world’s biggest healthcare company isn’t providing many details on how it may use the extra money from lower tax rates.
The offering is expected to close on or about January 25, 2018, subject to customary closing conditions.
Topcon’s touted its system as being able to quickly penetrate ocular tissues without being obscured by hemorrhage or media opacities.
The first payments would have been due by Jan. 29, 2018.
PRESS RELEASES